Market Cap 352.77M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,980,400
Avg Vol 2,777,720
Day's Range N/A - N/A
Shares Out 81.66M
Stochastic %K 83%
Beta 1.45
Analysts Strong Sell
Price Target $6.60

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
Vikingsstrade
Vikingsstrade Oct. 4 at 6:00 PM
$SRRK $SMLR $IMAB $BTAI Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
DARKP00L
DARKP00L Oct. 3 at 4:41 PM
$IMAB this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:34 PM
$ATOM $IMAB $ANY $NGNE Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
nurse_intern
nurse_intern Oct. 3 at 11:38 AM
$IMAB The company had no meaningful revenue in recent periods, relying on financing to sustain operations. Simply Wall St flags that earnings are forecast to decline ~11.9 % annually over the next 3 years, creating headwinds.
0 · Reply
notreload_ai
notreload_ai Oct. 3 at 11:08 AM
$IMAB's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink. https://notreload.xyz/i-mab-givastomig-stomach-cancer-treatment-game-changer/
0 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 10:55 AM
Leerink Partners has updated their rating for I-MAB ( $IMAB ) to Outperform with a price target of 9.
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 7:24 AM
$IMAB Excellent article that nails exactly where IMAB stands right now. So if you want to update your IMAB knowledge or get acquainted with IMAB, this is a must read. https://beyondspx.com/quote/IMAB/analysis/i-mab-s-strategic-rebirth-a-focused-pipeline-and-differentiated-immuno-oncology-drive-future-value-nasdaq-imab
0 · Reply
senior_nurse
senior_nurse Oct. 3 at 4:13 AM
$IMAB @Dividendkingg to run it smoother, you don't have to close all 30. You can do 10 at a time.
0 · Reply
senior_nurse
senior_nurse Oct. 3 at 3:52 AM
$IMAB @Dividendkingg Can't you close your 30 $5 calls before expiration not to worry so much?
0 · Reply
Dividendkingg
Dividendkingg Oct. 3 at 12:17 AM
$IMAB absolute tank. I hope my 30 $5 Oct 17 covered calls don’t get called away!!!
0 · Reply
Latest News on IMAB
I-Mab to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 6 weeks ago

I-Mab to Participate in September Investor Conferences


Everest Medicines Expands Strategic Investment in I-MAB

Aug 1, 2025, 8:56 AM EDT - 2 months ago

Everest Medicines Expands Strategic Investment in I-MAB


I-Mab to Present at Jefferies Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 4 months ago

I-Mab to Present at Jefferies Global Healthcare Conference


I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Mar 7, 2025, 7:00 AM EST - 7 months ago

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress


I-Mab to Participate at the Piper Sandler Healthcare Conference

Nov 21, 2024, 7:00 AM EST - 11 months ago

I-Mab to Participate at the Piper Sandler Healthcare Conference


I-Mab Reports Third Quarter 2024 Results

Nov 14, 2024, 7:00 AM EST - 11 months ago

I-Mab Reports Third Quarter 2024 Results


I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Nov 6, 2024, 7:00 AM EST - 11 months ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer


I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024, 4:01 PM EDT - 1 year ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024


I-MAB (IMAB) Q2 2024 Earnings Call Transcript

Aug 28, 2024, 11:50 AM EDT - 1 year ago

I-MAB (IMAB) Q2 2024 Earnings Call Transcript


I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024


I-Mab Announces Leadership Transitions

Jul 15, 2024, 7:30 AM EDT - 1 year ago

I-Mab Announces Leadership Transitions


I-MAB Filed 2023 Annual Report on Form 20-F

Apr 30, 2024, 7:00 AM EDT - 1 year ago

I-MAB Filed 2023 Annual Report on Form 20-F


I-Mab: Trading Below Net Cash With Multiple Upside Options

Feb 18, 2024, 3:28 AM EST - 1 year ago

I-Mab: Trading Below Net Cash With Multiple Upside Options


I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023


AbbVie terminates deal with I-Mab to develop cancer drug

Sep 22, 2023, 5:09 PM EDT - 2 years ago

AbbVie terminates deal with I-Mab to develop cancer drug

ABBV


I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Sep 13, 2023, 4:59 PM EDT - 2 years ago

I-Mab: Why This Company Trades At A Third The Value Of Its Cash


I-Mab (IMAB) Q2 2023 Earnings Call Transcript

Aug 17, 2023, 12:26 PM EDT - 2 years ago

I-Mab (IMAB) Q2 2023 Earnings Call Transcript


Vikingsstrade
Vikingsstrade Oct. 4 at 6:00 PM
$SRRK $SMLR $IMAB $BTAI Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
DARKP00L
DARKP00L Oct. 3 at 4:41 PM
$IMAB this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:34 PM
$ATOM $IMAB $ANY $NGNE Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
nurse_intern
nurse_intern Oct. 3 at 11:38 AM
$IMAB The company had no meaningful revenue in recent periods, relying on financing to sustain operations. Simply Wall St flags that earnings are forecast to decline ~11.9 % annually over the next 3 years, creating headwinds.
0 · Reply
notreload_ai
notreload_ai Oct. 3 at 11:08 AM
$IMAB's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink. https://notreload.xyz/i-mab-givastomig-stomach-cancer-treatment-game-changer/
0 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 10:55 AM
Leerink Partners has updated their rating for I-MAB ( $IMAB ) to Outperform with a price target of 9.
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 7:24 AM
$IMAB Excellent article that nails exactly where IMAB stands right now. So if you want to update your IMAB knowledge or get acquainted with IMAB, this is a must read. https://beyondspx.com/quote/IMAB/analysis/i-mab-s-strategic-rebirth-a-focused-pipeline-and-differentiated-immuno-oncology-drive-future-value-nasdaq-imab
0 · Reply
senior_nurse
senior_nurse Oct. 3 at 4:13 AM
$IMAB @Dividendkingg to run it smoother, you don't have to close all 30. You can do 10 at a time.
0 · Reply
senior_nurse
senior_nurse Oct. 3 at 3:52 AM
$IMAB @Dividendkingg Can't you close your 30 $5 calls before expiration not to worry so much?
0 · Reply
Dividendkingg
Dividendkingg Oct. 3 at 12:17 AM
$IMAB absolute tank. I hope my 30 $5 Oct 17 covered calls don’t get called away!!!
0 · Reply
eeyore1
eeyore1 Oct. 1 at 4:23 PM
$IMAB FDA won't accept new drug applications during government shutdown
0 · Reply
eeyore1
eeyore1 Oct. 1 at 4:02 PM
$IMAB Wall St notes that over the last 7 days, IMAB returned –3.6 %, underperforming relative to the biotech sector and broader market. A “death cross” in KDJ oscillator was pointed out as a bearish technical signal triggering selling. Media sentiment (over the last 7 days) is modest, with a sentiment score of ~0.42 (on a scale from –2 to +2) — not strongly positive. Short interest has increased (by ~15.8 % recently) per MarketBeat, which may reflect growing pessimism among some investors.
0 · Reply
Caresto
Caresto Oct. 1 at 1:18 PM
$IMAB Private payrolls in the United States experienced their largest decline in two-and-a-half years during September, according to data released Wednesday by payroll processing firm ADP. Companies shed a seasonally adjusted 32,000 jobs last month, marking the biggest drop since March 2023 and falling significantly short of expectations, as economists surveyed by Dow Jones had projected an increase of 45,000 jobs.
0 · Reply
highnihilism
highnihilism Oct. 1 at 9:31 AM
$LFWD Lifeward Trade Count: 13 | Total $: 3.2 K | 0.72 × 90-Day Avg $: 4.5 K | Call $: 3.2 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $BBC Virtus Lifesci Biotech Clinical Trials ETF Trade Count: 11 | Total $: 3.2 K | 1.17 × 90-Day Avg $: 2.8 K | Call $: 3.2 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $AOSL Alpha & Omega Trade Count: 13 | Total $: 4.5 K | 0.22 × 90-Day Avg $: 20.9 K | Call $: 3.2 K | Put $: 1.3 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $IMAB I-Mab Trade Count: 11 | Total $: 3.2 K | 0.16 × 90-Day Avg $: 20.2 K | Call $: 3.2 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
Caresto
Caresto Oct. 1 at 4:20 AM
Over a 3-year horizon, $IMAB exhibits a negative Sharpe ratio, meaning that its returns after adjusting for volatility have underperformed the risk-free rate (or benchmark) when risk is taken into account. According to GuruFocus, its 3-year Sharpe ratio is about –0.63. That implies that the volatility it's exposed to has not been compensated by excess returns. In the same period, IMAB’s Sortino ratio (which penalizes only downside variability) is also negative (≈ –0.82 per a GuruFocus listing) , suggesting that its downside risk (loss deviations) has been significant relative to returns. Additionally, its beta (sensitivity to market movements) is elevated: GuruFocus lists a beta ~1.3. This suggests that IMAB tends to amplify market swings (i.e., more reactive to general market risk).
0 · Reply
Dividendkingg
Dividendkingg Oct. 1 at 1:26 AM
$IMAB tomorrow going to be epic!
0 · Reply
grizzly3
grizzly3 Sep. 30 at 7:05 PM
$IMAB short float; July 15:0.76%; July 31:0.8%; Aug 15: 2.7%; Aug 29:1.98%; Sep 15:2.1%
0 · Reply
grizzly3
grizzly3 Sep. 30 at 5:31 PM
$IMAB The federal government may enter a shutdown beginning at 12:01 a.m. on Wednesday, October 1, 2025, if there is a lapse in federal government funding. This may weigh on stocks tomorrow and beyond. If you’re holding positions, it might be wise to think about taking profits or trimming exposure today.
0 · Reply
_www_larval_com_
_www_larval_com_ Sep. 30 at 2:27 PM
$IMAB has reverted -3% lower to 6% (~2Mv) moments ago, 10/17 options, follow for more volatility.
0 · Reply
Dividendkingg
Dividendkingg Sep. 30 at 1:29 PM
$IMAB just like I called yesterday.
0 · Reply
Dividendkingg
Dividendkingg Sep. 29 at 2:31 PM
$IMAB would like to see a run to 3.60 near term. Downward pressure here
0 · Reply
Dividendkingg
Dividendkingg Sep. 29 at 1:48 PM
$IMAB down again?!?
0 · Reply